C4 Therapeutics (CCCC) Competitors

$3.56 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$3.55 -0.01 (-0.25%)

As of 05/22/2026 07:50 PM Eastern

CCCC vs. CMPS, URGN, IMTX, MAZE, and SLS

Should you buy C4 Therapeutics stock or one of its competitors? MarketBeat compares C4 Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with C4 Therapeutics include Compass Pathways (CMPS), Urogen Pharma (URGN), Immatics (IMTX), Maze Therapeutics (MAZE), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry.

How does C4 Therapeutics compare to Compass Pathways?

C4 Therapeutics (NASDAQ:CCCC) and Compass Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 46.2% of Compass Pathways shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by insiders. Comparatively, 2.8% of Compass Pathways shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Compass Pathways had 11 more articles in the media than C4 Therapeutics. MarketBeat recorded 13 mentions for Compass Pathways and 2 mentions for C4 Therapeutics. Compass Pathways' average media sentiment score of 0.60 beat C4 Therapeutics' score of 0.00 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

C4 Therapeutics currently has a consensus price target of $7.75, suggesting a potential upside of 117.70%. Compass Pathways has a consensus price target of $20.58, suggesting a potential upside of 74.29%. Given C4 Therapeutics' higher probable upside, equities analysts plainly believe C4 Therapeutics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Compass Pathways has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. Compass Pathways' return on equity of -31.07% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Compass Pathways	N/A	-31.07%	-11.40%

C4 Therapeutics has a beta of 2.77, indicating that its stock price is 177% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.39, indicating that its stock price is 139% more volatile than the broader market.

C4 Therapeutics has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	10.95	-$104.99M	-$1.19	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

Summary

C4 Therapeutics and Compass Pathways tied by winning 8 of the 16 factors compared between the two stocks.

How does C4 Therapeutics compare to Urogen Pharma?

C4 Therapeutics (NASDAQ:CCCC) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, C4 Therapeutics and C4 Therapeutics both had 2 articles in the media. Urogen Pharma's average media sentiment score of 0.26 beat C4 Therapeutics' score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Urogen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

C4 Therapeutics has a beta of 2.77, indicating that its share price is 177% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market.

Urogen Pharma has a net margin of -94.83% compared to C4 Therapeutics' net margin of -297.76%. Urogen Pharma's return on equity of 0.00% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Urogen Pharma	-94.83%	N/A	-62.85%

C4 Therapeutics has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	10.95	-$104.99M	-$1.19	N/A
Urogen Pharma	$109.79M	12.82	-$153.49M	-$2.75	N/A

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

C4 Therapeutics currently has a consensus target price of $7.75, indicating a potential upside of 117.70%. Urogen Pharma has a consensus target price of $36.67, indicating a potential upside of 26.92%. Given C4 Therapeutics' higher possible upside, equities analysts plainly believe C4 Therapeutics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Urogen Pharma beats C4 Therapeutics on 9 of the 16 factors compared between the two stocks.

How does C4 Therapeutics compare to Immatics?

Immatics (NASDAQ:IMTX) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Immatics currently has a consensus target price of $19.00, suggesting a potential upside of 63.51%. C4 Therapeutics has a consensus target price of $7.75, suggesting a potential upside of 117.70%. Given C4 Therapeutics' higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, C4 Therapeutics had 1 more articles in the media than Immatics. MarketBeat recorded 2 mentions for C4 Therapeutics and 1 mentions for Immatics. Immatics' average media sentiment score of 0.00 equaled C4 Therapeutics'average media sentiment score.

Company	Overall Sentiment
Immatics	Neutral
C4 Therapeutics	Neutral

Immatics has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.77, indicating that its stock price is 177% more volatile than the broader market.

C4 Therapeutics has a net margin of -297.76% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
C4 Therapeutics	-297.76%	-50.68%	-33.22%

C4 Therapeutics has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	28.53	-$222.26M	-$1.99	N/A
C4 Therapeutics	$35.95M	10.95	-$104.99M	-$1.19	N/A

64.4% of Immatics shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 3.3% of Immatics shares are held by insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

C4 Therapeutics beats Immatics on 10 of the 15 factors compared between the two stocks.

How does C4 Therapeutics compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

Maze Therapeutics has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the broader market.

78.8% of C4 Therapeutics shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Maze Therapeutics had 21 more articles in the media than C4 Therapeutics. MarketBeat recorded 23 mentions for Maze Therapeutics and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.00 beat Maze Therapeutics' score of -0.68 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maze Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. Maze Therapeutics' return on equity of -36.62% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
C4 Therapeutics	-297.76%	-50.68%	-33.22%

Maze Therapeutics currently has a consensus price target of $66.00, suggesting a potential upside of 156.01%. C4 Therapeutics has a consensus price target of $7.75, suggesting a potential upside of 117.70%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Maze Therapeutics is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

C4 Therapeutics has lower revenue, but higher earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	8.52	-$131.12M	-$2.53	N/A
C4 Therapeutics	$35.95M	10.95	-$104.99M	-$1.19	N/A

Summary

Maze Therapeutics beats C4 Therapeutics on 9 of the 17 factors compared between the two stocks.

How does C4 Therapeutics compare to SELLAS Life Sciences Group?

C4 Therapeutics (NASDAQ:CCCC) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by insiders. Comparatively, 1.4% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 2 mentions for C4 Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 0.32 beat C4 Therapeutics' score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SELLAS Life Sciences Group	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

C4 Therapeutics has a beta of 2.77, indicating that its share price is 177% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.24, indicating that its share price is 124% more volatile than the broader market.

C4 Therapeutics currently has a consensus target price of $7.75, indicating a potential upside of 117.70%. SELLAS Life Sciences Group has a consensus target price of $10.00, indicating a potential upside of 28.53%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SELLAS Life Sciences Group has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. SELLAS Life Sciences Group's return on equity of -47.12% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

SELLAS Life Sciences Group has lower revenue, but higher earnings than C4 Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	10.95	-$104.99M	-$1.19	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Summary

C4 Therapeutics beats SELLAS Life Sciences Group on 9 of the 15 factors compared between the two stocks.

Get C4 Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CCCC vs. The Competition

Export

Metric	C4 Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$393.63M	$3.37B	$6.43B	$12.32B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-2.99	18.91	21.00	25.66
Price / Sales	10.95	329.35	615.84	111.99
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	1.68	7.09	10.37	7.14
Net Income	-$104.99M	$24.45M	$3.57B	$335.98M
7 Day Performance	10.56%	5.45%	6.00%	3.56%
1 Month Performance	23.61%	2.43%	3.51%	2.54%
1 Year Performance	157.97%	62.98%	34.12%	35.05%

C4 Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CCCC C4 Therapeutics	1.4658 of 5 stars	$3.56 flat	$7.75 +117.7%	+158.0%	$393.63M	$35.95M	N/A	150
CMPS Compass Pathways	3.8309 of 5 stars	$10.04 -5.0%	$20.58 +105.1%	+170.9%	$1.37B	N/A	N/A	120	Analyst Forecast
URGN Urogen Pharma	3.3466 of 5 stars	$27.61 -3.4%	$36.67 +32.8%	+589.5%	$1.37B	$109.79M	N/A	200	Gap Up
IMTX Immatics	2.122 of 5 stars	$10.20 -4.0%	$19.00 +86.3%	+127.4%	$1.37B	$54.60M	N/A	260
MAZE Maze Therapeutics	2.1475 of 5 stars	$24.15 -1.4%	$66.00 +173.3%	+150.8%	$1.36B	$167.50M	N/A	121	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CCCC) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

C4 Therapeutics (CCCC) Competitors

CCCC vs. CMPS, URGN, IMTX, MAZE, and SLS

How does C4 Therapeutics compare to Compass Pathways?

Summary

How does C4 Therapeutics compare to Urogen Pharma?

Summary

How does C4 Therapeutics compare to Immatics?

Summary

How does C4 Therapeutics compare to Maze Therapeutics?

Summary

How does C4 Therapeutics compare to SELLAS Life Sciences Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

C4 Therapeutics (CCCC) Competitors

CCCC vs. CMPS, URGN, IMTX, MAZE, and SLS

How does C4 Therapeutics compare to Compass Pathways?

Do institutionals and insiders believe in CCCC or CMPS?

Does the media favor CCCC or CMPS?

Do analysts rate CCCC or CMPS?

Is CCCC or CMPS more profitable?

Which has more risk & volatility, CCCC or CMPS?

Which has higher earnings and valuation, CCCC or CMPS?

Summary

How does C4 Therapeutics compare to Urogen Pharma?

Does the media prefer CCCC or URGN?

Which has more volatility and risk, CCCC or URGN?

Is CCCC or URGN more profitable?

Which has stronger earnings & valuation, CCCC or URGN?

Do institutionals and insiders believe in CCCC or URGN?

Do analysts recommend CCCC or URGN?

Summary

How does C4 Therapeutics compare to Immatics?

Do analysts recommend IMTX or CCCC?

Does the media prefer IMTX or CCCC?

Which has more volatility & risk, IMTX or CCCC?

Is IMTX or CCCC more profitable?

Which has higher valuation and earnings, IMTX or CCCC?

Do institutionals & insiders have more ownership in IMTX or CCCC?

Summary

How does C4 Therapeutics compare to Maze Therapeutics?

Which has more volatility and risk, MAZE or CCCC?

Do institutionals and insiders hold more shares of MAZE or CCCC?

Does the media prefer MAZE or CCCC?

Is MAZE or CCCC more profitable?

Do analysts recommend MAZE or CCCC?

Which has preferable valuation & earnings, MAZE or CCCC?

Summary

How does C4 Therapeutics compare to SELLAS Life Sciences Group?

Do insiders and institutionals have more ownership in CCCC or SLS?

Does the media refer more to CCCC or SLS?

Which has more volatility and risk, CCCC or SLS?

Do analysts prefer CCCC or SLS?

Is CCCC or SLS more profitable?

Which has stronger valuation and earnings, CCCC or SLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools